These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 30142943)

  • 1. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
    Cicero AFG; Colletti A; Bellentani S
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28906453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.
    Salomone F; Godos J; Zelber-Sagi S
    Liver Int; 2016 Jan; 36(1):5-20. PubMed ID: 26436447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Angelico F
    Br J Clin Pharmacol; 2017 Jan; 83(1):88-95. PubMed ID: 26852185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients.
    Curcio A; Romano A; Cuozzo S; Nicola AD; Grassi O; Schiaroli D; Nocera GF; Pironti M
    Medicina (Kaunas); 2020 Oct; 56(10):. PubMed ID: 33080906
    [No Abstract]   [Full Text] [Related]  

  • 6. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G; Ni Y; Nagata N; Xu L; Ota T
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
    Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
    Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.
    Alberti G; Gana JC; Santos JL
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33212947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food components with antifibrotic activity and implications in prevention of liver disease.
    Bae M; Park YK; Lee JY
    J Nutr Biochem; 2018 May; 55():1-11. PubMed ID: 29268106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet.
    Amato A; Caldara GF; Nuzzo D; Baldassano S; Picone P; Rizzo M; Mulè F; Di Carlo M
    Nutrients; 2017 May; 9(5):. PubMed ID: 28505074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
    Ezhilarasan D; Lakshmi T
    Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease in children: focus on nutritional interventions.
    Yang M; Gong S; Ye SQ; Lyman B; Geng L; Chen P; Li DY
    Nutrients; 2014 Oct; 6(11):4691-705. PubMed ID: 25353664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.